72 results about "Obese Mice" patented technology

The invention relates to an application of an Sdccag3 gene in preparation of a weight-reducing medicine for regulating glucose and lipid metabolism. The Sdccag3 gene is used as an action target to be applied to preparation or screening of the weight-reducing medicine for regulating glucose and lipid metabolism, and the nucleotide sequence of the Sdccag3 gene is as shown in SEQ ID No. 1. According to the application disclosed by the invention, the specific overexpressed Sdccag3 in adipose tissues in a mouse body can obviously inhibit the increase of the blood fat level, and the overexpressed Sdccag3 can also obviously improve the poor glucose tolerance, improve the insulin sensitivity, reduce the levels of serum triglyceride, cholesterol and low-density lipoprotein cholesterol of an obese mouse, improve the poor glucose tolerance and improve the insulin sensitivity. The insulin sensitivity is improved, obesity-related glycolipid metabolism is effectively regulated and controlled, the effect of reducing blood lipid and blood sugar is achieved, and the compound can be used for preparing weight-losing drugs for reducing blood lipid and blood sugar.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

The invention discloses application of phlebopus portentosus polysaccharide in preparation of medicines or foods for regulating intestinal flora, reducing blood fat and reducing weight, and belongs to the technical field of biological medicines. The research on the effect of the phlebopus portentosus polysaccharide on obese model mice finds that the polysaccharide can reduce the occurrence of cardiovascular diseases such as atherosclerosis and the like, and has the effect of protecting the liver from being damaged. In addition, the liver injury state of the obese mouse is obviously relieved, the content of total short-chain fatty acid (SCFAs) of the obese mouse is increased, the species diversity of intestinal flora of the mouse is adjusted to a certain extent, and the colony composition is optimized.

The invention relates to application of 9-cis-retinoic acid in preparation of products for treating, preventing or improving obesity, and belongs to the technical field of biological medicine. Experimental evaluation of obese mice induced by high-fat diet proves that the 9-cis-retinoic acid can reduce blood fat and improve the glycometabolism function, and lipid accumulation of the liver is improved mainly by increasing expression of main regulatory protein PPAR-alpha oxidized by liver beta, so that the 9-cis-retinoic acid can be used for preparing medicines for treating obesity. The traditional Chinese medicine composition can be used for treating, preventing or improving metabolic symptoms caused by high fat diet, and a new strategy is provided for treating obesity and related metabolic syndromes. Besides, 9-cis-retinoic acid is a natural active metabolite of vitamin A, does not show obvious toxic reaction in animal experiments, and has better biocompatibility.

The invention relates to a preparation method and application of a medicine-food homologous compound with weight-losing and lipid-lowering effects. According to the present invention, the weight of the obese mouse can be reduced by 23.23% at most, the serum total cholesterol is reduced, the leptin secretion is reduced, AST (aspartate transaminase) and ALT (alanine transaminase) have no significant difference compared to the model mouse, the volume of epididymal fat and inguinal fat cells is reduced, the number of cells in unit area is significantly increased, the fatty liver sample is relieved, the TMEM26 gene expression in the epididymal fat is significantly increased, and the weight of the obese mouse can be significantly reduced; the expression quantity of the UCP1 gene in brown fat is obviously increased. The traditional Chinese medicine composition adopts medicinal and edible substances as raw materials, is widely applicable to people, is more suitable for prevention and treatment of chronic diseases, is safe and effective, and causes little damage to liver and kidney after long-term use.

Mouse models of obesity associated with human MC4R missense mutations are provided. Human mutations introduced with CRISPR / Cas9 into the mouse MC4R gene lead to an severely obese mouse phenotype in mice with a heterozygous genotype.

The application discloses a polypeptide composition for treating obesity and related metabolic diseases and application thereof. The polypeptide composition comprises polypeptide 1 and polypeptide 2, wherein the amino acid sequence of the polypeptide 1 is shown as SEQ ID NO. 1, can be specifically combined with the CD105 receptor on the surface of MSCs and the AdipoR1 receptor of adipocytes; the amino acid sequence of the polypeptide 2 is shown as SEQ ID NO. 2, can target adipose tissue and regulate glycolipid metabolism. The polypeptide composition is combined with fat-derived mesenchymal stem cells (MSCs) and applied to a high-fat-diet obese mouse model, and the results show that the composition has a significant synergistic effect in reducing body fat, improving the morphology of adipose tissue, regulating serum metabolic factors and inflammatory factors, and has no obvious organ toxicity. The application provides a new effective strategy and a safe and reliable pharmaceutical composition for treating obesity and related metabolic diseases.

The application discloses a norchizhiol triterpenoid compound, a preparation method and application thereof. The norchizhiol triterpenoid compound norchizhiol A can be quickly prepared from Ganoderma lucidum. The test proves that the norchizhiol A can inhibit the accumulation of triglyceride in the differentiation process of 3T3L1 preadipocytes. The norchizhiol A can also effectively reduce the weight increase and liver coefficient of high-fat-diet-induced obese mice, regulate the blood lipid level of the obese mice, and significantly intervene and improve the lipoprotein distribution of the body. The compound can be used for preparing anti-obesity and lipid-lowering medicines.

This invention discloses the application of α-hydroxyisocaproic acid in weight loss and lipid reduction, belonging to the fields of biopharmaceutical manufacturing, biomedical applications, and functional food development. This invention confirms the application of α-hydroxyisocaproic acid in weight loss; this compound can inhibit weight gain in high-fat diet-induced obese mouse models, reduce body fat, and decrease the area of ​​adipocytes in high-fat diet-induced obese mouse models. Compared to GLP-1 receptor weight-loss drugs that reduce weight by suppressing appetite, the compound α-hydroxyisocaproic acid intervenes in and prevents obesity by accelerating fat metabolism, thereby achieving weight reduction. This invention provides a safe and effective new strategy for weight loss and lipid reduction.

This invention discloses a strain of *Lactobacillus warfarinii* Z40 and its applications. The taxonomic name of *Lactobacillus warfarinii* Z40 is... Limosilactobacillus walteri Z40, deposited on May 18, 2026 at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20261007. This invention isolates a strain of *Lactobacillus warfarinii* Z40 from the intestines of healthy children. It exhibits certain resistance to gastric acid and high bile salts in intestinal fluid, and is non-hemolytic. Mouse model experiments have verified that it can effectively reduce the body weight of obese mice, decrease visceral fat accumulation, lower blood lipid levels, improve abnormal glucose metabolism in mice, and significantly reduce intestinal permeability, thereby improving abnormal phenotypes in mice in multiple ways. It can be applied to products related to weight loss, lowering blood lipids, lowering blood sugar, and improving intestinal barrier function.

The invention belongs to the technical field of biological medicines, and particularly relates to a composite active polypeptide composition with a weight losing effect and a preparation method thereof. The composite active polypeptide composition comprises NT analogue polypeptide ELP3, mulberry leaf polypeptide, balsam pear polypeptide, sea cucumber polypeptide and oyster peptide; the amino acid sequence of the NT analogue polypeptide ELP3 is as shown in SEQ ID NO. 1. According to the present invention, the artificial peptide fragment AYYKSQWLVNGEGTP is added to the end of the wild type NT, such that the gastric acid secretion can be inhibited, and the activity of the alpha-amylase can be significantly inhibited; the NT analogue polypeptide ELP3 and various polypeptide components are matched to achieve a synergistic effect, so that the blood fat metabolism condition of obese mice can be effectively improved, and the fat weight of the mice is reduced; meanwhile, the food intake of the mice can be remarkably inhibited, so that the purpose of reducing the weight of the mice is achieved, and a good weight-losing effect is achieved.

The present invention relates to a preparation method of an exocrine protein Pc and its application in regulating intestinal flora. The fungal-derived Pc protein directly interacts with a protein in the intestinal microorganisms that has exocrine properties and contains a β-N-acetylglucosaminidase (GL) domain and inhibits its enzymatic activity, thereby regulating the proliferation of beneficial microorganisms by alleviating cellular iron and ROS pressure. The Pc protein can regulate the expression of bifunctional autolysins, and can enrich beneficial Staphylococcus bacteria with bifunctional autolysins in the insect intestine, or can enrich beneficial Lachnospiraceae bacteria with bifunctional autolysins in the intestines of healthy mammalian mice, or can enrich Blautia bacteria in the intestines of obese mice induced by a high-fat diet, or can enrich Akkermansia bacteria in the intestines of mice with DSS-induced colitis. The Pc protein can significantly reduce the formation of biofilms of Staphylococcus aureus (S. aureus) with bifunctional autolysins. Pc protein can be used as a new potential prebiotic to regulate the proliferation of beneficial intestinal microorganisms with bifunctional autolysins, and has potential application value in the preparation of food, medicine and disease treatment.

This invention belongs to the field of pharmaceutical technology, specifically relating to the use of a 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative or its pharmaceutically acceptable salt, or its tautomer, meso compound, racemic compound, enantiomer, diastereomer, or pharmaceutical composition thereof as an active ingredient in the preparation of drugs for the prevention or treatment of obesity and obesity-related metabolic diseases. The 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative of this invention has significant therapeutic effects on obesity and related metabolic diseases. In obese mice induced by a high-fat diet and high-fructose water intake, gavage administration for 6 weeks showed that, compared with the high-fat control group, it inhibited more than 70% of the mice's weight gain, with no significant difference in food intake and water intake, demonstrating good clinical application prospects.

The invention discloses a polypeptide composition for treating obesity and related metabolic diseases and application of the polypeptide composition. The polypeptide composition comprises a polypeptide 1 and a polypeptide 2, the amino acid sequence of the polypeptide 1 is as shown in SEQ ID NO.1, and the polypeptide 1 can be specifically combined with a CD105 receptor on the surface of MSCs and an adipose cell AdipoR1 receptor; the amino acid sequence of the polypeptide 2 is as shown in SEQ ID NO.2, and the polypeptide 2 can target adipose tissues and regulate and control glycolipid metabolism. The polypeptide composition and adipose-derived mesenchymal stem cells (MSCs) are jointly applied to a high-fat diet obesity mouse model, and the result shows that the composition has a remarkable synergistic effect in the aspects of reducing body fat, improving adipose tissue form and regulating serum metabolic factors and inflammatory factors, and has no obvious organ toxicity. The invention provides a novel effective strategy and a safe and reliable pharmaceutical composition for treating obesity and related metabolic diseases.

This invention discloses the application of a high-N-acetylglycine-producing *Lactobacillus reuteri* strain in alleviating obesity-related metabolic diseases, belonging to the field of microbial technology. The *Lactobacillus reuteri* NO1 strain of this invention (…) Limosilactobacillus reuteri (NO1) possesses the ability to produce N-acetylglycine in vitro. This strain can inhibit weight gain in obese mice without affecting food intake; improve glucose tolerance in obese mice while reducing blood glucose, serum insulin, and insulin resistance index; regulate liver triglycerides in obese mice, and alleviate liver tissue damage. The *Lactobacillus reuteri* strain described in this invention has very broad application prospects for preparing anti-obesity pharmaceutical compositions and fermented foods.

The application discloses ecdysterone-low molecular weight fructan composite microspheres with fat-reducing and muscle-increasing functions, and a preparation method and application thereof, and belongs to the technical field of biological medicine and functional food. The composite microspheres have a core-shell structure, the inner core is a calcium alginate gel, the outer shell is chitosan, the inner core co-encapsulates ecdysterone and low molecular weight fructan, and the mass ratio of the two is 0.8-1.2:1. The preparation adopts a liquid drop microfluidic technology combined with an internal gelation method to form the inner core, and adopts a post-crosslinking method to coat the outer shell. The composite microspheres are regular in shape, uniform in particle size, high in encapsulation rate, good in stability, excellent in pH response slow-release and anti-degradation characteristics in the gastrointestinal tract. In-vivo pharmacological experiments prove that the composite microspheres can reduce the body weight and body fat rate of obese mice, increase the lean meat content and muscle strength, realize synergistic effects of fat reduction and muscle increase, and can be used for preparing drugs or functional food for improving obesity-related muscle loss, low-muscle obesity and related metabolic syndrome.

The invention discloses a traditional Chinese medicine composition and application thereof in prevention or treatment of obesity, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from rhizoma pinellinae praeparata, caulis bambusae in taeniam, fructus aurantii immaturus, pericarpium citri reticulatae, poria cocos, radix scutellariae, fried hawthorn fruits, raw coix seeds, leeches, fresh ginger, Chinese dates and raw licorice roots according to specific weight parts. On the basis of a classic famous prescription, namely gallbladder-warming decoction, according to the traditional Chinese medicine pathology of qi loss of three jiao and damp heat-phlegm stasis-collateral obstruction, medicines such as scutellaria baicalensis, fried hawthorn, raw semen coicis, leech and the like are added, so that the fat-reducing gallbladder-warming decoction is formed. The composition has the effects of eliminating dampness and phlegm, clearing heat and eliminating blood stasis, and tonifying spleen and dredging collaterals. Animal experiments show that the traditional Chinese medicine composition can significantly reduce the weight, body fat and blood fat of obese mice and improve fatty degeneration of livers; clinical research shows that the weight, BMI, waistline, blood fat and traditional Chinese medicine syndromes of obese patients can be effectively improved, the total effective rate reaches 94.4%, and safety is good.

The invention belongs to the technical field of microorganisms, and particularly relates to a strain of Caribik Meyer yeast and application thereof. The strain is isolated from natural plant enzymes. In an in-vitro test, the strain has relatively high TG (Triglyceride) degradation capacity and T-CHO (T-CHO) degradation capacity; in an in-vivo test, the enzyme prepared by fermenting a seed solution of the strain can effectively reduce the weight, fat coefficient and blood fat level of obese mice and relieve pathological changes of fatty liver, has no obvious toxic or side effect, and can be used as a candidate for replacing weight-reducing medicines, so that the enzyme has good practical application value.

The invention discloses an FSTL1 overexpression adeno-associated virus and application thereof, and aims to efficiently deliver a mouse source FSTL1 gene into mouse muscle cells by virtue of a virus infection mechanism by utilizing the targeting property of AAV1 type to muscle tissues. FSTL1 is overexpressed in mouse muscle tissue, muscle insulin signal transduction and glucose metabolism processes are adjusted from multiple dimensions of insulin signal channel activation, glucose transporter regulation and control and the like, and therefore the insulin sensitivity and glucose metabolism conditions of muscles in an obese mouse model are improved.

The invention provides application of propyl gallate in preparation of anti-obesity drugs or functional food for weight management, and belongs to the field of biological medicine technology and food. The invention discloses that the propyl gallate has the health benefit of positively regulating basic metabolism for the first time, and the propyl gallate can obviously reduce the weight of obese mice induced by high fat diet, reduce body fat, effectively relieve obesity and improve metabolic conditions such as glucose tolerance and insulin resistance; and brown fat can be activated to produce heat, respiratory metabolism and energy consumption are enhanced, and a new way is opened up for preventing and / or treating obesity. Propyl gallate is an edible substance, is high in safety and oxidation resistance, and is widely used as a food antioxidant, so that propyl gallate can be used for preparing anti-obesity drugs or functional foods for weight management, and has a good application prospect.

The invention belongs to the field of biological medicine, and particularly relates to a construction method and application of a spontaneous obesity model of a systemic GPX3 knock-gene mouse. The construction method comprises the following steps: preparing a precisely targeted GPX3 gene, knocking out a gene editing tool mixture of a specific segment (SEQ ID NO.1) of the GPX3 gene, transferring the gene editing tool mixture into a fertilized egg, and mating a mouse until a stably inherited GPX3 gene knockout homozygous mouse is obtained. The GPX3 is knocked out through the CRISPR / Cas9 technology, the spontaneous obese mouse model which cannot be achieved in the prior art is successfully obtained, the model can simulate obesity-related multi-organ lesions and diabetes mellitus progress, and a reliable tool is provided for obesity mechanism research and drug research and development.

The use of an RINL gene and an antagonist thereof in the treatment of obesity. Specifically provided is the use of an RINL gene or an encoded protein thereof. The RINL gene or the encoded protein thereof is used for one of the following: (1) as a marker for diagnosing, detecting or prognosing obesity; (2) in the preparation of a reagent or kit for diagnosing or detecting obesity; or (3) in the preparation of a drug for treating obesity. RINL-KO significantly improves glucose tolerance and insulin resistance of obese mice, ameliorates the accumulation of subcutaneous fat and visceral fat thereof, alleviates the inflammation of adipose tissue thereof, and greatly improves the health of the mice. Therefore, an RINL antagonist has the potential to efficiently treat obesity. It is proposed for the first time that RINL is used as a new target in the preparation of a drug for treating obesity, which is of great significance for new drug screening, and also provides a new idea for the treatment of obesity.

The application relates to the field of biological medicine, and discloses an application of pachyman-derived extracellular vesicles and high-abundance miRNA thereof in relieving obesity. Cell experiments and animal experiments find that the pachyman-derived extracellular vesicles and high-abundance miRNA thereof can up-regulate the expression amount of key genes for brownification of white fat in 3T3-L1 adipocytes and mice in vivo, significantly improve glucose tolerance and insulin resistance of obese mice, and obviously relieve liver steatosis and lipid accumulation. Not only can the pachyman-derived extracellular vesicles and high-abundance miRNA thereof improve obesity from a phenotype, but also can regulate lipid metabolism, and have the value of being applied to preparation of medicines for preventing or relieving obesity and related metabolic complications.

The invention discloses an application of premna microphylla pectin in preparation of a product for preventing and improving diet-induced obesity. The premna pubescens pectin is prepared from premna pubescens leaves as a raw material through extraction, purification and other processes. According to the present invention, the research on the high fat diet induced obese mouse model finds that the body lipid metabolism is regulated by remodeling the intestinal flora structure, particularly reducing the ratio of the phylum firmicutes to the phylum bacteroides, and specifically enriching the beneficial flora such as Muribacaceae and the like by using the premna microphylla pectin; experimental results prove that the premna microphylla pectin can significantly inhibit pathological hypertrophy of adipocytes, reduce visceral fat accumulation, effectively control weight gain and improve dyslipidemia and liver fatty degeneration, and has good biological safety.

The present application relates to a kaurane diterpenoid compound D-33 extracted and separated from the roots of Euphorbia griffithii Hook., a preparation method and uses thereof. Bioactivity tests show that the compound D-33 has a significant weight loss effect in a high-fat diet-induced obese mouse model, can effectively activate uncoupling protein 1 (UCP1) in vitro, and can be used for preparing a thermogenic anti-obesity drug.

The invention relates to the field of medical preparations, in particular to application of ingenol in preparation of a medicine for treating liver injury of postmenopausal women. The ingenol intervenes in OVX to induce a postmenopausal obese mouse, and the ingenol is proved to be capable of remarkably reducing the weight and fat content of the mouse, reducing serum TC, TG and LDL-c level rise, improving hepatocyte swelling and reducing the number of liver fat droplets, and also capable of remarkably reducing serum AST and ALT level rise caused by OVX and relieving liver injury induced by OVX. Therefore, the ingenol can be used for effectively treating the liver injury of the postmenopausal women, and can be used for preparing a medicine for treating the liver injury of the postmenopausal women and a medicine for reducing the level of a liver injury marker in serum. The method can provide a new direction and strategy for future development and application of ingenol.

The invention provides application of nifurazide or a pharmaceutically acceptable derivative thereof and a pharmaceutical composition, and belongs to the technical field of biological medicines. The application comprises application of nifurazil in preparation of drugs for reducing food intake and / or inhibiting appetite. The nifurazil does not depend on blood sugar regulation and intestines and stomach, and does not cause side effects of nausea and vomiting; the action target of the nifurazil is not located in the peripheral nervous system but acts on the central nervous system, and the nifurazil can be used for remarkably reducing the intake of common food and high-fat food of mice and inhibiting the appetite of the mice in a mode of activating Glp1-r, so that the weight of the obese mice is remarkably reduced. Therefore, the nifurazil has the potential of treating the obesity and can be applied to preparation of the medicine for treating the obesity.

The invention discloses a microneedle raw material composition as well as a microneedle and a sonodynamic system formed by the microneedle raw material composition. The microneedle raw material composition comprises a zinc-based porphyrin metal organic framework MOF (Zn-TCPP) modified by mPEG-PEI. The sonodynamic system provided by the invention can kill redundant white fat cells. Obese mice treated with this ultrasound gene therapy show significant improvements in glucose tolerance and insulin sensitivity, successfully achieving weight loss and inhibiting weight rebound.

This invention discloses the application of sodium mannoside in the preparation of drugs for treating obesity and non-alcoholic fatty liver disease (NAFLD). Studies in this invention show that sodium mannoside has the effects of controlling body weight, improving glucose and lipid metabolism, enhancing insulin sensitivity, improving glucose tolerance, and preventing NAFLD. It can be used to prepare therapeutic drugs for metabolic diseases such as obesity caused by a long-term high-fat diet. Sodium mannoside can protect obese mice from liver lipotoxicity caused by a high-fat diet, providing more effective drugs for the prevention and treatment of obesity and NAFLD.

The embodiment of the invention provides an effect evaluation system for preventing and treating obesity, and relates to the technical field of analysis. The system comprises a feeding device used for containing multiple groups of obese mouse models, and the multiple groups of obese mouse models comprise experimental group mice, normal group mice and model group mice; the collecting device is used for collecting the liver tissues of the multiple groups of obese mouse models fed for the preset duration; wherein the mice in the experimental group are fed with to-be-experimented articles and high-fat feed, the mice in the model group are fed with high-fat feed, and the mice in the normal group are fed with normal feed; the measuring device is used for measuring the level of liver inflammatory factors in the liver tissue of each group of obese mouse models, and the liver inflammatory factors comprise at least one of the following items: tumor necrosis factor-alpha, interleukin-6 or interleukin-1beta; and the evaluation device is used for evaluating the obesity prevention and treatment effect of the to-be-experimented article based on the liver inflammatory factor levels of the multiple groups of obese mouse models.